eg5-in-1

Eg5-IN-1 is a potent inhibitor of the kinesin family of motor proteins (Eg5) with an IC50 value of 1.97 µM for Eg5.Eg5-IN-1 can be used in cancer research.

S-trityl-L-Cysteine is a non-natural amino acid and an inhibitor of Eg5, also known as KSP and Kif11, a mitotic kinesin necessary for mitotic spindle formation. S-trityl-L-Cysteine inhibits the ATPase activity of Eg5 in basal and microtubule-stimulated states (IC50s = 1,000 and 140 nM, respectively). It is selective for Eg5 over nine other human kinesins in an enzyme-coupled assay. It reversibly inhibits Eg5-driven microtubule sliding velocity with an IC50 value of 500 nM using X. laevis recombinant Eg5. It induces cell cycle arrest in HeLa cells (IC50 = 700 nM), reversibly halting the cell cycle in the mitotic phase by inhibiting the separation of duplicated chromosomes and preventing bipolar spindle formation. S-trityl-L-Cysteine inhibits the growth of cancer cells in vitro when tested against the National Cancer Institute (NCI) 60 human cancer cell line panel (average GI50 = 1.3 μM) and in mouse xenograft models.

NVP-BQS481 (Compound 1) is a selective inhibitor of spindle motor protein 5 (Eg5), with an IC50 of less than 0.5 nM. It demonstrates significant anti-mitotic and anti-tumor activities, exhibiting an IC50 of 0.09 nM against SK-OV-3ip cells. NVP-BQS481 is suitable for use as a cytotoxic payload in the synthesis of antibody-drug conjugates (ADCs).

LP-6 is a drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). LP-6 consists of an Eg5 inhibitor and a linker [1].

Eg5-IN-2 (Compound Scaffold B (4)), with an IC50 of less than 0.5 nM, acts as an effective Eg5 inhibitor. This compound is suitable for use as an ADC payload in the synthesis of ADCs [1].